España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Spyre Therapeutics
SYRE
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$24.42
0.07
0.29%
At close: -
$24.42
0.00
0.00%
After Hours: 4:00 PM EDT
Get Report
Comment
Spyre Therapeutics (SYRE) Forecast
News
Earnings
Spyre Therapeutics (SYRE) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Spyre Therapeutics (NASDAQ:SYRE) Stock
Spyre Therapeutics Stock (NASDAQ: SYRE)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, December 18, 2024
Spyre Therapeutics Added To The Nasdaq Biotec...
Benzinga Newsdesk
Wednesday, December 11, 2024
Jones Trading Initiates Coverage On Spyre The...
Benzinga Newsdesk
Monday, December 02, 2024
Spyre Therapeutics Announces First Participan...
Benzinga Newsdesk
Tuesday, November 19, 2024
Reported Earlier, Spyre Therapeutics Prices $...
Benzinga Newsdesk
Monday, November 18, 2024
Spyre Therapeutics Announces Proposed $200M P...
Benzinga Newsdesk
Wednesday, November 13, 2024
Baird Maintains Outperform on Spyre Therapeut...
Benzinga Newsdesk
Tuesday, November 12, 2024
Spyre Therapeutics shares are trading lower. ...
Benzinga Newsdesk
Spyre Therapeutics Announced Interim Phase 1 ...
Benzinga Newsdesk
Monday, November 11, 2024
Spyre Therapeutics To Host Conference Call An...
Benzinga Newsdesk
Thursday, November 07, 2024
Spyre Therapeutics Q3 EPS $(1.36) Misses $(0....
Benzinga Newsdesk
Friday, October 25, 2024
Guggenheim Maintains Buy on Spyre Therapeutic...
Benzinga Newsdesk
Tuesday, October 15, 2024
Paragon Therapeutics Granted Spyre Therapeuti...
Benzinga Newsdesk
Monday, October 14, 2024
Spyre Therapeutics Announces Expected Acceler...
Benzinga Newsdesk
Wednesday, September 04, 2024
Wedbush Initiates Coverage On Spyre Therapeut...
Benzinga Newsdesk
Wednesday, August 07, 2024
Spyre Therapeutics Q2 EPS $(0.86) Beats $(0.9...
Benzinga Newsdesk
Tuesday, July 16, 2024
Evercore ISI Group Initiates Coverage On Spyr...
Benzinga Newsdesk
Tuesday, June 18, 2024
Spyre Therapeutics Has Initiated Dosing Of He...
Benzinga Newsdesk
Wednesday, May 15, 2024
On May 14, 2024, Paragon Therapeutics Announc...
Benzinga Newsdesk
Monday, May 13, 2024
Wells Fargo Maintains Overweight on Spyre The...
Benzinga Newsdesk
Friday, May 10, 2024
BTIG Maintains Buy on Spyre Therapeutics, Rai...
Benzinga Newsdesk
Thursday, May 09, 2024
Spyre Therapeutics Q1 2024 GAAP EPS $(1.20) M...
Benzinga Newsdesk
Thursday, May 02, 2024
Baird Initiates Coverage On Spyre Therapeutic...
Benzinga Newsdesk
Tuesday, March 26, 2024
Stifel Reiterates Buy on Spyre Therapeutics, ...
Benzinga Newsdesk
Stifel Maintains Buy on Spyre Therapeutics, R...
Benzinga Newsdesk
Monday, March 18, 2024
Spyre Therapeutics shares are trading lower a...
Benzinga Newsdesk
Spyre Therapeutics Announces $180M Private Pl...
Benzinga Newsdesk
Tuesday, March 05, 2024
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
Friday, March 01, 2024
Spyre Therapeutics shares are trading higher ...
Benzinga Newsdesk
Wells Fargo Upgrades Spyre Therapeutics to Ov...
Benzinga Newsdesk
Thursday, February 29, 2024
Spyre Therapeutics Q4 EPS $(4.05) Up From $(5.00) YoY
Happy Mohamed
Thursday, February 08, 2024
Spyre Therapeutics Announces Three Abstracts ...
Benzinga Newsdesk
Wednesday, December 20, 2023
BTIG Initiates Coverage On Spyre Therapeutics...
Benzinga Newsdesk
Monday, December 18, 2023
Stifel Maintains Buy on Spyre Therapeutics, R...
Benzinga Newsdesk
Monday, December 11, 2023
Guggenheim Initiates Coverage On Spyre Therap...
Benzinga Newsdesk
Jefferies Initiates Coverage On Spyre Therape...
Benzinga Newsdesk
Friday, December 08, 2023
Reported Earlier, Spyre Therapeutics Secures ...
Benzinga Newsdesk
Wednesday, November 29, 2023
TD Cowen Initiates Coverage On Spyre Therapeu...
Benzinga Newsdesk
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
